Amphista Therapeutics is developing medicines for hard to treat diseases using next generation targeted protein degradation approaches. Our portfolio uses our own novel protein degrading mechanisms which build on the strengths of current protein degradation approaches whilst directly addressing their limitations.
Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.
Targeted Protein Degradation
Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Drop us a line
We are here to answer any question you may have
BioCity, Bo’Ness Rd, Newhouse, Chapelhall, Motherwell, ML1 5UH, UK
158-160 North Gower Street, London, England, NW1 2ND, UK